Omega-3 Fatty Acids and Cardiovascular Disease: New Developments and Applications
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The omega-3 fatty acids (FA) found in fish oils, eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively), have been extensively studied therapeutically in a wide variety of disease conditions, but in none more than cardiovascular disease (CVD). Our review summarizes mechanisms of action, recent meta-analyses of CVD outcome trials, sources (fish and supplements), and recommendations for use of omega-3 FA in clinical practice. With the ability to now measure the omega-3 FA biostatus through blood tests, patients can achieve cardioprotective levels by either taking fish oil supplements or simply eating more oily fish. Two omega-3 FA formulations (both in the ethyl ester form) have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with very high triglyceride levels (> 500 mg/dL); one contains both EPA and DHA, whereas the other contains only EPA. The agents have been extensively tested in 2 patient populations, those with very high triglycerides and those with triglycerides between 200 and 500 mg/dL while on background statin therapy. In general, treatment with EPA+DHA appears to lower patient triglycerides more effectively, but in those patients with very high triglyceride levels, use of EPA+DHA also raised low-density lipoprotein cholesterol levels, whereas EPA alone did not. Both formulations, at doses that do not lower triglycerides, have been shown to reduce CVD events in some, but not all, studies. Given the favorable risk-to-benefit ratio for these essentially nutritional agents, use is expected to continue to expand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Self-citationBurr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111
Self-citationResolvins and protectins in inflammation resolution
Serhan, C. N., & Petasis, N. A. (2011) · Chemical Reviews · doi:10.1021/cr100396c · Cited by 996
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
Thies, F., Garry, J. M., Yaqoob, P., Rerkasem, K., Williams, J., Shearman, C. P., Gallagher, P. J., Calder, P. C., & Grimble, R. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12468-3 · Cited by 739
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
Balk, E. M., Lichtenstein, A. H., Chung, M., Kupelnick, B., Chew, P., & Lau, J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.012 · Cited by 732
Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials
Geleijnse, J. M., Giltay, E. J., Grobbee, D. E., Donders, A. R. T., & Kok, F. J. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00010 · Cited by 700
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.084 · Cited by 644
Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives
Harris, W. S., Miller, M., Tighe, A. P., Davidson, M. H., & Schaefer, E. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.008 · Cited by 552
Self-citationn–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Wada, M., DeLong, C. J., Hong, Y. H., Rieke, C. J., Song, I., Sidhu, R. S., Yuan, C., Warnock, M., Schmaier, A. H., Yokoyama, C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703169200 · Cited by 400
Effect of Fish Oil on Heart Rate in Humans: A Meta-Analysis of Randomized Controlled Trials
Mozaffarian, D., Geelen, A., Brouwer, I. A., Geleijnse, J. M., Zock, P. L., & Katan, M. B. (2005) · Circulation · doi:10.1161/circulationaha.105.556886 · Cited by 399
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Raitt, M. H., Connor, W. E., Morris, C., Kron, J., Halperin, B., Chugh, S. S., McClelland, J., Cook, J., MacMurdy, K., Swenson, R., et al. (2005) · JAMA · doi:10.1001/jama.293.23.2884 · Cited by 371
Kwak (2012) · doi:10.1001/archinternmed.2012.262 · Cited by 368
Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake
Leaf, A., Albert, C. M., Josephson, M., Steinhaus, D., Kluger, J., Kang, J. X., Cox, B., Zhang, H., & Schoenfeld, D. (2005) · Circulation · doi:10.1161/circulationaha.105.549527 · Cited by 364
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis
Pan, A., Chen, M., Chowdhury, R., Wu, J. H., Sun, Q., Campos, H., Mozaffarian, D., & Hu, F. B. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.044040 · Cited by 329
Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis
Eslick, G. D., Howe, P. R. C., Smith, C., Priest, R., & Bensoussan, A. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.03.092 · Cited by 299
Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging
Tan, Z. S., Harris, W. S., Beiser, A. S., Au, R., Himali, J. J., Debette, S., Pikula, A., DeCarli, C., Wolf, P. A., Vasan, R. S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318249f6a9 · Cited by 265
Self-citationBioavailability of marine n-3 fatty acid formulations
Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., & Schmidt, E. B. (2010) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.06.007 · Cited by 256
Safety and efficacy of Omacor in severe hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199710000-00011 · Cited by 252
Self-citationOmega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966168 · Cited by 201
Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00301-3 · Cited by 179
Brouwer, I. A., Raitt, M. H., Dullemeijer, C., Kraemer, D. F., Zock, P. L., Morris, C., Katan, M. B., Connor, W. E., Camm, J. A., Schouten, E. G., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp003 · Cited by 120
Tatsuno, I., Saito, Y., Kudou, K., & Ootake, J. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.01.006 · Cited by 42
Cited by
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“For secondary prevention of CHD, Harris et al.130 noted that there have been 9 large randomized trials with omega-3 fatty acid supplements, of which 4 reported positive (favorable) results,131–134 4 were neutral,135–138 and 1 study was negative (i.e., suggested an adverse effect).139 The positive trials were conducted…”
BackgroundInfluentialDietary Polyunsaturated Fatty Acids (PUFAs): Uses and Potential Health Benefits
Kapoor, B., Kapoor, D., Gautam, S., Singh, R., & Bhardwaj, S. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00363-3 · Cited by 418
Chang, C.-H., Tseng, P.-T., Chen, N.-Y., Lin, P.-C., Lin, P.-Y., Chang, J. P. C., Kuo, F.-Y., Lin, J., Wu, M.-C., & Su, K.-P. (2018) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.01.001 · Cited by 103
“There has been much evidence showing their benefits for not only various physical conditions[2-9] but also several mental disorders [10-16].”
BackgroundPourrajab, B., Sohouli, M. H., Amirinejad, A., Fatahi, S., Găman, M.-A., & Shidfar, F. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1895062 · Cited by 33
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
Metadata
- Authors
- Harris, W. S., Dayspring, T. D., & Moran, T. J.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2013-11
- Volume
- 125
- Issue
- 6
- Pages
- 100-113
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2128584128
- Cited by
- 79
- References
- 36
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.